ATTENTION LFST SHAREHOLDERS: Investors who lost money on LifeStance Health Group, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of LifeStance Health Group, Inc. ("LifeStance") (NASDAQ:LFST) concerning possible violations of federal securities laws. LifeStance is the subject of a report published by Hindenburg Research on February 1, 2024, titled: "LifeStance: A Private Equity-Backed Mental Health Rollup Headed For A Breakdown.
Does LifeStance Health (LFST) Have the Potential to Rally 54.84% as Wall Street Analysts Expect?
The mean of analysts' price targets for LifeStance Health (LFST) points to a 54.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The Schall Law Firm Examines LifeStance Health Group Inc And Urges Impacted Investors To Engage In Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Examines LifeStance Health Group Inc And Urges Impacted Investors To Engage In Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Examines LifeStance Health Group Inc And Urges Impacted Investors To Engage In Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Examines LifeStance Health Group Inc And Urges Impacted Investors To Engage In Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Examining LifeStance Health Group Inc And Encourages Impacted Investors To Initiate Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
All You Need to Know About LifeStance Health (LFST) Rating Upgrade to Strong Buy
LifeStance Health (LFST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The Schall Law Firm Is Examining LifeStance Health Group Inc And Urges Impacted Investors To Begin Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LifeStance Health Group Inc Is Under The Schall Law Firm's Scrutiny And Affected Investors Are Encouraged To Initiate Conversations
LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LifeStance Health Group Inc Is Under Examination By The Schall Law Firm, Affected Investors Are Encouraged To Initiate Conversations
LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Urges Impacted Investors To Start Dialogue, LifeStance Health Group Inc Is Under Scrutiny
LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeStance Health Group, Inc. ("LifeStance" or "the Company") (NASDAQ:LFST) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
